GSK-3, a Key Player in Alzheimer's Disease

Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: Drug Discovery and Development

Volumn , Issue , 2006, Pages 105-124

  Hernández, Félix ^a   Avila, Jesús ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

GSK 3 regulation and Alzheimer's disease (AD); Tau phosphorylation by GSK 3; Tau phosphorylation by GSK 3 and Tau aggregation

Indexed keywords

EID: 84889336973     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470052174.ch6     Document Type: Chapter

References (107)

1. Gotz J., Chen F., van Dorpe J., Nitsch R.M. (2001). Formation of neurofibrillary tangles in P301l Tau transgenic mice induced by Abeta 42 fibrils. Science, 293, 1491-1495.
2. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science, 293, 1487-1491.
3. Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., Ferreira A. (2002). Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA, 99, 6364-6369.
4. Ishiguro K., Omori A., Takamatsu M., Sato K., Arioka M., Uchida T., Imahori K. (1992). Phosphorylation sites on Tau by Tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci. Lett., 148, 202-206.
5. Ishiguro K., Shiratsuchi A., Sato S., Omori A., Arioka M., Kobayashi S., Uchida T., Imahori K. (1993). Glycogen synthase kinase 3 beta is identical to Tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett., 325, 167-172.
6. Cohen P., Frame S. (2001). The renaissance of GSK3. Nat. Rev. Mol. Cell. Biol., 2, 769-776.
7. Woodgett J.R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J., 9, 2431-2438.
8. Takashima A., Noguchi K., Michel G., Mercken M., Hoshi M., Ishiguro K., Imahori K. (1996). Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of Tau protein kinase I glycogen synthase kinase-3 beta. Neurosci. Lett., 203, 33-36.
9. Busciglio J., Lorenzo A., Yeh J., Yankner B.A. (1995). beta-Amyloid fibrils induce Tau phosphorylation and loss of microtubule binding. Neuron., 14, 879-888.
10. Ferreira A., Lu Q., Orecchio L., Kosik K.S. (1997). Selective phosphorylation of adult Tau isoforms in mature hippocampal neurons exposed to fibrillar A beta. Mol. Cell. Neurosci., 9, 220-234.
11. Takashima A., Noguchi K., Sato K., Hoshino T., Imahori K. (1993). Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc. Natl. Acad. Sci. USA, 90, 7789-7793.
12. Alvarez G., Munoz-Montano J.R., Satrustegui J., Avila J., Bogonez E., Díaz-Nido J. (1999). Lithium protects cultured neurons against beta-amyloidinduced neurodegeneration. FEBS Lett., 453, 260-264.
13. Lovestone S., Reynolds C.H., Latimer D., Davis D.R., Anderton B.H., Gallo J.M., Hanger D., Mulot S., Marquardt B., Stabel S., et al. (1994). Alzheimer's disease-like phosphorylation of the microtubule-associated protein Tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol., 4, 1077-1086.
14. Hong M., Chen D.C.R., Klein P.S., Lee V.M.Y. (1997). Lithium reduces Tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem., 272, 25326-25332.
15. Munoz-Montano J.R., Moreno F.J., Avila J., Díaz-Nido J. (1997). Lithium inhibits Alzheimer's disease-like Tau protein phosphorylation in neurons. FEBS Lett., 411, 183-188.
16. Yamaguchi H., Ishiguro K., Uchida T., Takashima A., Lemere C.A., Imahori K. (1996). Preferential labeling of Alzheimer neurofibrillary tangles with antisera for Tau protein kinase (TPK) I glycogen synthase kinase-3 beta and cyclindependent kinase 5, a component of TPK II. Acta. Neuropathol., 92, 232-241.
17. Imahori K., Uchida T. (1997). Physiology and pathology of Tau protein kinases in relation to Alzheimer's disease. J. Biochem. (Tokyo), 121, 179-188.
18. Pei J.J., Braak E., Braak H., GrundkeIqbal I., Iqbal K., Winblad B., Cowburn R.F. (1999). Distribution of active glycogen synthase kinase 3 beta (GSK-3 beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol., 58, 1010-1019.
19. Frame S., Cohen P. (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem. J., 359, 1-16.
20. Jope R.S., Johnson G.V. (2004). The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci, 29, 95-102.
21. Hansen L., Arden K.C., Rasmussen S.B., Viars C.S., Vestergaard H., Hansen T., Moller A.M., Woodgett J.R., Pedersen O. (1997). Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3alpha and beta isoforms in patients with NIDDM. Diabetologia, 40, 940-946.
22. Shaw P.C., Davies A.F., Lau K.F., Garcia-Barcelo M., Waye M.M., Lovestone S., Miller C.C., Anderton B.H. (1998). Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and-3 beta encoding genes. Genome, 41, 720-727.
23. Mukai F., Ishiguro K., Sano Y., Fujita S.C. (2002). Alternative splicing isoform of Tau protein kinase I/glycogen synthase kinase 3beta. J. Neurochem., 81, 1073-1083.
24. Lau K.F., Miller C.C., Anderton B.H., Shaw P.C. (1999). Molecular cloning and characterization of the human glycogen synthase kinase-3beta promoter. Genomics, 60, 121-128.
25. Russ C., Lovestone S., Powell J.F. (2001). Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease. Mol. Psychiat., 6, 320-324.
26. Hughes K., Nikolakaki E., Plyte S.E., Totty N.F., Woodgett J.R. (1993). Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J., 12, 803-808.
27. Bax B., Carter P.S., Lewis C., Guy A.R., Bridges A., Tanner R., Pettman G., Mannix C., Culbert A.A., Brown M.J., Smith D.G., Reith A.D. (2001). The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-Catenin phosphorylation. Structure (Camb.), 9, 1143-1152.
28. Kim L., Liu J., Kimmel A.R. (1999). The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification. Cell, 99, 399-408.
29. Lesort M., Jope R.S., Johnson G.V. (1999). Insulin transiently increases Tau phosphorylation: Involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J. Neurochem., 72, 576-584.
30. Cole A., Frame S., Cohen P. (2004). Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem. J., 377, 249-255.
31. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., Cowburn R.F. (1999). Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol., 58, 1010-1019.
32. Tomidokoro Y., Ishiguro K., Harigaya Y., Matsubara E., Ikeda M., Park J.M., Yasutake K., Kawarabayashi T., Okamoto K., Shoji M. (2001). Abeta amyloidosis induces the initial stage of Tau accumulation in APP(Sw) mice. Neurosci. Lett., 299, 169-172.
33. ter Haar E., Coll J.T., Austen D.A., Hsiao H.M., Swenson L., Jain J. (2001). Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat. Struct. Biol., 8, 593-596.
34. Dajani R., Fraser E., Roe S.M., Young N., Good V., Dale T.C., Pearl L.H. (2001). Crystal structure of glycogen synthase kinase 3 beta: Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell, 105, 721-732.
35. Xie L., Helmerhorst E., Taddei K., Plewright B., Van Bronswijk W., Martins R. (2002). Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci., 22, RC221.
36. Ferrer I., Gomez-Isla T., Puig B., Freixes M., Ribe E., Dalfo E., Avila J. (2005). Current advances on different kinases involved in Tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr. Alzheimer Res., 2, 3-18.
37. Aberle H., Bauer A., Stappert J., Kispert A., Kemler R. (1997). beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J., 16, 3797-3804.
38. Zhang Z., Hartmann H., Do V.M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Sommer B., van de Wetering M., Clevers H., Saftig P., De Strooper B., He X., Yankner B.A. (1998). Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature, 395, 698-702.
39. Weihl C.C., Miller R.J., Roos R.P. (1999). The role of beta-catenin stability in mutant PS1-associated apoptosis. Neuroreport, 10, 2527-2532.
40. Takashima A., Murayama M., Murayama O., Kohno T., Honda T., Yasutake K., Nihonmatsu N., Mercken M., Yamaguchi H., Sugihara S., Wolozin B. (1998). Presenilin 1 associates with glycogen synthase kinase-3 beta and its substrate Tau. Proc. Natl. Acad. Sci. USA, 95, 9637-9641.
41. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. (2001). Decreased nuclear beta-catenin, Tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J., 20, 27-39.
42. Aplin A.E., Gibb G.M., Jacobsen J.S., Gallo J.M., Anderton B.H. (1996). In vitro phosphorylation of the cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. J. Neurochem., 67, 699-707.
43. Aplin A.E., Jacobsen J.S., Anderton B.H., Gallo J.M. (1997). Effect of increased glycogen synthase kinase-3 activity upon the maturation of the amyloid precursor protein in transfected cells. Neuroreport, 8, 639-643.
44. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. (2003). GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature, 423, 435-439.
45. Ryder J., Su Y., Liu F., Li B., Zhou Y., Ni B. (2003). Divergent roles of GSK3 and CDK5 in APP processing. Biochem. Biophys. Res. Commun., 312, 922-929.
46. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med., 2, 864-870.
47. Brunkan A.L., Goate A.M. (2005). Presenilin function and gamma-secretase activity. J. Neurochem., 93, 769-792.
48. Selkoe D.J. (1996). Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem., 271, 18295-18298.
49. Hardy J., Selkoe D.J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 297, 353-356.
50. Murayama O., Tomita T., Nihonmatsu N., Murayama M., Sun X.Y., Honda T., Iwatsubo T., Takashima A. (1999). Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci. Lett., 265, 61-63.
51. Dermaut B., Kumar-Singh S., Engelborghs S., Theuns J., Rademakers R., Saerens J., Pickut B.A., Peeters K., van den Broeck M., Vennekens K., Claes S., Cruts M., Cras P., Martin J.J., Van Broeckhoven C., De Deyn P.P. (2004). A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. Ann. Neurol., 55, 617-626.
52. Weihl C.C., Ghadge G.D., Kennedy S.G., Hay N., Miller R.J., Roos R.P. (1999). Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB. J. Neurosci., 19, 5360-5369.
53. Baki L., Shioi J., Wen P., Shao Z., Schwarzman A., Gama-Sosa M., Neve R., Robakis N.K. (2004). PS1 activates PI3K thus inhibiting GSKynthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol., 58, 1010-1019.
54. Morishimakawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K., Ihara Y. (1995). Proline-directed and non-proline-directed phosphorylation of PHF-Tau. J. Biol. Chem., 270, 823-829.
55. Cho J.H., Johnson G.V. (2003). Glycogen synthase kinase 3beta phosphorylates Tau at both primed and unprimed sites: Differential impact on microtubule binding. J. Biol. Chem., 278, 187-193.
56. Noble W., Olm V., Takata K., Casey E., Mary O., Meyerson J., Gaynor K., LaFrancois J., Wang L., Kondo T., Davies P., Burns M., Veeranna, Nixon R., Dickson D., Matsuoka Y., Ahlijanian M., Lau L.F., Duff K. (2003). Cdk5 is a key factor in Tau aggregation and tangle formation in vivo. Neuron., 38, 555-565.
57. Sengupta A., Wu Q.L., GrundkeIqbal I., Iqbal K., Singh T.J. (1997). Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human Tau by cdk5. Mol. Cell. Biochem., 167, 99-105.
58. Nishimura I., Yang Y., Lu B. (2004). PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers Tau toxicity in Drosophila. Cell, 116, 671-682.
59. Singh T.J., Zaidi T., Grundke-Iqbal I., Iqbal K. (1995). Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein Tau by nonproline-dependent protein kinases. FEBS Lett., 358, 4-8.
60. Engel T., Lucas J.J., Gomez-Ramos P., Moran M.A., Avila J., Hernandez F. (2005). Cooexpression of FTDP-17 Tau and GSK-3β in transgenic mice induce Tau polymerization and neurodegeneration. Neurobiol. Aging, (in press).
61. Lauckner J., Frey P., Geula C. (2003). Comparative distribution of Tau phosphorylated at Ser262 in pre-tangles and tangles. Neurobiol. Aging, 24, 767-776.
62. Jiang H., Guo W., Liang X., Rao Y. (2005). Both the establishment and the maintenance of neuronal polarity require active mechanisms: Critical roles of GSK-3beta and its upstream regulators. Cell, 120, 123-135.
63. Hernandez F., Lucas J.J., Cuadros R., Avila J. (2003). GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different Tau isoforms. Neurobiol. Aging, 24, 1087-1094.
64. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., PickeringBrown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., deGraaff E., Wauters E., vanBaren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Che L.K., Norton J., Morris J.C., Reed L.A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F., Tannenberg T., Dodd P.R., Hayward N., Kwok J.B.J., Schofield P.R., Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B.A., Hardy J., Goate A., vanSwieten J., Mann D., et al. (1998). Association of missense and 5-splice-site mutations in Tau with the inherited dementia FTDP-17. Nature, 393, 702-705.
65. Goedert M., Crowther R.A., Spillantini M.G. (1998). Tau mutations cause frontotemporal dementias. Neuron., 21, 955-958.
66. Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., Ghetti B. (1998). Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA, 95, 7737-7741.
67. Hasegawa M., Smith M.J., Goedert M. (1998). Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett., 437, 207-210.
68. Hong M., Zhukareva V., VogelsbergRagaglia V., Wszolek Z., Reed L., Miller B.I., Geschwind D.H., Bird T.D., McKeel D., Goate A., Morris J.C., Wilhelmsen K.C., Schellenberg G.D., Trojanowski J.Q., Lee V.M.Y. (1998). Mutationspecific functional impairments in distinct Tau isoforms of hereditary FTDP-17. Science, 282, 1914-1917.
69. Jackson G.R., Wiedau-Pazos M., Sang T.K., Wagle N., Brown C.A., Massachi S., Geschwind D.H. (2002). Human wild-type Tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron., 34, 509-519.
70. Wittmann C.W., Wszolek M.F., Shulman J.M., Salvaterra P.M., Lewis J., Hutton M., Feany M.B. (2001). Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science, 293, 711-714.
71. Heutink P. (2000). Untangling Tau-related dementia. Hum. Mol. Genet., 9, 979-986.
72. Hernandez F., Perez M., Lucas J.J., Mata A.M., Bhat R., Avila J. (2004). Glycogen synthase kinase-3 plays a crucial role in Tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J. Biol. Chem., 279, 3801-3806.
73. Buee L., Delacourte A. (1999). Comparative biochemistry of Tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol., 9, 681-693.
74. Bueescherrer V., Hof P.R., Buee L., Leveugle B., Vermersch P., Perl D.P., Olanow C.W., Delacourte A. (1996). Hyperphosphorylated Tau proteins differentiate corticobasal degeneration and Pick's disease. Acta. Neuropathol. (Berlin), 91, 351-359.
75. Ferrer I., Barrachina M., Puig B. (2002). Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated Tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta. Neuropathol. (Berlin), 104, 583-591.
76. Bancher C., Brunner C., Lassmann H., Budka H., Jellinger K., Wiche G., Seitelberger F., Grundke I.I., Iqbal K., Wisniewski H.M. (1989). Accumulation of abnormally phosphorylated Tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res., 477, 90-99.
77. Gordon-Krajcer W., Yang L., Ksiezak-Reding H. (2000). Conformation of paired helical filaments blocks dephosphorylation of epitopes shared with fetal Tau except Ser199/202 and Ser202/Thr205. Brain Res., 856, 163-175.
78. Schneider A., Biernat J., von Bergen M., Mandelkow E., Mandelkow E.M. (1999). Phosphorylation that detaches Tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry, 38, 3549-3558.
79. Perez M., Cuadros R., Smith M.A., Perry G., Avila J. (2000). Phosphorylated, but not native, Tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal. FEBS Lett., 486, 270-274.
80. Santa-Maria I., Hernandez F., Martin C.P., Avila J., Moreno F.J. (2004). Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of Tau into fibrillar polymers. Biochemistry, 43, 2888-2897.
81. Serpell L.C., Sunde M., Blake C.C. (1997). The molecular basis of amyloidosis. Cell. Mol. Life Sci., 53, 871-887.
82. Sadqi M., Hernandez F., Pan U., Perez M., Schaeberle M.D., Avila J., Munoz V. (2002). Alpha-helix structure in Alzheimer's disease aggregates of Tau-protein. Biochemistry, 41, 7150-7155.
83. Minoura K., Tomoo K., Ishida T., Hasegawa H., Sasaki M., Taniguchi T. (2002). Amphipathic helical behavior of the third repeat fragment in the Tau microtubule-binding domain, studied by (1)H NMR spectroscopy. Biochem. Biophys. Res. Commun., 294, 210-214.
84. Minoura K., Yao T.M., Tomoo K., Sumida M., Sasaki M., Taniguchi T., Ishida T. (2004). Different associational and conformational behaviors between the second and third repeat fragments in the Tau microtubule-binding domain. Eur. J. Biochem., 271, 545-552.
85. Hiraoka S., Yao T.M., Minoura K., Tomoo K., Sumida M., Taniguchi T., Ishida T. (2004). Conformational transition state is responsible for assembly of microtubule-binding domain of Tau protein. Biochem. Biophys. Res. Commun., 315, 659-663.
86. Scott C.W., Spreen R.C., Herman J.L., Chow F.P., Davison M.D., Young J., Caputo C.B. (1993). Phosphorylation of recombinant Tau by cAMP-dependent protein kinase: Identification of phosphorylation sites and effect on microtubule assembly. J. Biol. Chem., 268, 1166-1173.
87. Mendieta J., Fuertes M.A., Kunjishapatham R., Santa-Maria I., Moreno F.J., Alonso C., Gago F., Munoz V., Avila J., Hernandez F. (2005). Phosphorylation modulates the alpha-helical structure and polymerization of a peptide from the third Tau microtubule-binding repeat. Biochim. Biophys. Acta., 1721, 16-26.
88. Hoshi M., Takashima A., Noguchi K., Murayama M., Sato M., Kondo S., Saitoh Y., Ishiguro K., Hoshino T., Imahori K. (1996). Regulation of mitochondrial pyruvate dehydrogenase activity by Tau protein kinase 1/glycogen synthase kinase 3 beta in brain. Proc. Nat. Acad. Sci. USA, 93, 2719-2723.
89. Gonzalez-Billault C., Jimenez-Mateos E.M., Caceres A., Díaz-Nido J., Wandosell F., Avila J. (2004). Microtubule-associated protein 1B function during normal development, regeneration, and pathological conditions in the nervous system. J. Neurobiol., 58, 48-59.
90. Sanchez C., Díaz-Nido J., Avila J. (2000). Phosphorylation of microtubuleassociated protein 2 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function. Prog. Neurobiol., 61, 133-168.
91. Yoshimura T., Kawano Y., Arimura N., Kawabata S., Kikuchi A., Kaibuchi K. (2005). GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell, 120, 137-149.
92. Klein P.S., Melton D.A. (1996). A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA, 93, 8455-8459.
93. Ryves W.J., Harwood A.J. (2001). Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun., 280, 720-725.
94. Ryves W.J., Dajani R., Pearl L., Harwood A.J. (2002). Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem. Biophys. Res. Commun., 290, 967-972.
95. Martinez A., Alonso M., Castro A., Perez C., Moreno F.J. (2002). First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem., 45, 1292-1299.
96. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., Greengard P., Biernat J., Wu Y.Z., Mandelkow E.M., Eisenbrand G., Meijer L. (2001). Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal Tau phosphorylation in Alzheimer's disease: A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem., 276, 251-260.
97. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Roxbee Cox L., Mills D., Brown M.J., Haigh D., Ward R.W., Smith D.G., Murray K.J., Reith A.D., Holder J.C. (2000). Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol., 7, 793-803.
98. Bhat R., Xue Y., Berg S., Hellberg S., Ormo M., Nilsson Y., Radesater A.C., Jerning E., Markgren P.O., Borgegard T., Nylof M., Gimenez-Cassina A., Hernandez F., Lucas J.J., Diaz-Nido J., Avila J. (2003). Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem., 278, 45937-45945.
99. Munoz-Montano J.R., Moreno F.J., Avila J., DiazNido J. (1999). Downregulation of glycogen synthase kinase-3 beta (GSK-3 beta) protein expression during neuroblastoma IMR-32 cell differentiation. J. Neurosci. Res., 55, 278-285.
100. Chen R.W., Chuang D.M. (1999). Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J. Biol. Chem., 274, 6039-6042.
101. King T.D., Bijur G.N., Jope R.S. (2001). Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res., 919, 106-114.
102. Moore G.J., Bebchuk J.M., Wilds I.B., Chen G., Manji H.K. (2000). Lithiuminduced increase in human brain grey matter. Lancet, 356, 1241-1242.
103. Lim F., Hernandez F., Lucas J.J., Gomez-Ramos P., Moran M.A., Avila J. (2001). FTDP-17 mutations in Tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol. Cell. Neurosci., 18, 702-714.
104. Perez M., Hernandez F., Lim F., Díaz-Nido J., Avila J. (2003). Chronic lithium treatment decreases mutant Tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis., 5, 301-308.
105. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., Gaynor K., Wang L., LaFrancois J., Feinstein B., Burns M., Krishnamurthy P., Wen Y., Bhat R., Lewis J., Dickson D., Duff K. (2005). Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA, 102, 6990-6995.
106. Yamamoto A., Lucas J.J., Hen R. (2000). Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell, 101, 57-66.
107. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K.H. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science, 309, 476-481.